Increased survivin expression contributes to apoptosis-resistance in IPF fibroblasts (original) (raw)

[1]

Collard, H.R., et al. (2012) Burden of illness in idiopathic pulmonary fibrosis. Journal of Medical Economics, 15, 829-835. doi:10.3111/13696998.2012.680553

[2]

Raghu, G., et al. (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. American Journal of Respiratory and Critical Care Medicine, 183, 788-824. doi:10.1164/rccm.2009-040GL

[3]

Navaratnam, V., et al. (2011) The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax, 66, 462-467. doi:10.1136/thx.2010.148031

[4]

Maher, T.M. (2012) Idiopathic pulmonary fibrosis: Pathobiology of novel ap-proaches to treatment. Clinics in Chest Medicine, 33, 69-83. doi:10.1016/j.ccm.2011.11.002

[5]

Ley, B., Collard, H.R. and King Jr., T.E. (2011) Clinical course and pre-diction of survival in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Med-icine, 183, 431-440. doi:10.1164/rccm.201006-0894CI

[6]

Ding, Q., et al. (2011) New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis. Drugs, 71, 981-1001. doi:10.2165/11591490-000000000-00000

[7]

King Jr., T.E., Pardo, A. and Selman, M. (2011) Idiopathic pul-monary fibrosis. Lancet, 378, 1949-1961. doi:10.1016/S0140-6736(11)60052-4

[8]

Horowitz, J.C. and Thannickal, V.J. (2006) Idiopathic pulmonary fibrosis: New concepts in pathogenesis and implications for drug therapy. Treatments in Respiratory Medicine, 5, 325-342. doi:10.2165/00151829-200605050-00004

[9]

Desmouliere, A., Chaponnier, C. and Gabbiani, G. (2005) Tissue repair, contraction, and the myofibroblast. Wound Repair and Regeneration, 13, 7-12. doi:10.1111/j.1067-1927.2005.130102.x

[10]

Hinz, B., et al. (2012) Recent developments in myofibroblast biology: Paradigms for connective tissue remodeling. American Journal of Pathology, 180, 1340-1355. doi:10.1016/j.ajpath.2012.02.004

[11]

Laurent, G.J., et al. (2008) Escape from the matrix: Multiple mechanisms for fibroblast activation in pulmonary fibrosis. Proceedings of the American Thoracic Society, 5, 311-315. doi:10.1513/pats.200710-159DR

[12]

Desmouliere, A., et al. (1995) Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. American Journal of Pathology, 146, 56-66.

[13]

Tomasek, J.J., et al. (2002) Myofibroblasts and mechano-regulation of connective tissue remodelling. Nature Reviews Molecular Cell Biolog, 3, 349-363. doi:10.1038/nrm809

[14]

Thannickal, V.J. and Horowitz, J.C. (2006) Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proceedings of the American Thoracic Society, 3, 350- 356. doi:10.1513/pats.200601-001TK

[15]

Cha, S.I., et al. (2010) Compartmentalized expression of c-FLIP in lung tissues of patients with idiopathic pulmonary fibrosis. American Journal of Respiratory Cell and Molecular Bi-ology, 42, 140-148. doi:10.1165/rcmb.2008-0419OC

[16]

Lepparanta, O., et al. (2010) Transcription factor GATA- 6 is expressed in quiescent myofibroblasts in idiopathic pulmonary fibrosis. American Journal of Respiratory Cell and Molecular Bi-ology, 42, 626-632. doi:10.1165/rcmb.2009-0021OC

[17]

Korfei, M., et al. (2008) Epithelial endoplasmic reticulum stress and apop-tosis in sporadic idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine, 178, 838-846. doi:10.1164/rccm.200802-313OC

[18]

Maher, T.M., et al. (2010) Diminished prostaglandin E2 contributes to the apoptosis paradox in idiopathic pulmo- nary fibrosis. American Journal of Respiratory and Cri- tical Care Medicine, 182, 73-82. doi:10.1164/rccm.200905-0674OC

[19]

Buhling, F., et al. (2005) Altered expression of mem- brane-bound and soluble CD95/Fas contributes to the re- sistance of fibrotic lung fibroblasts to FasL induced apoptosis. Respiratory Research, 6, 37. doi:10.1186/1465-9921-6-37

[20]

Horowitz, J.C., et al. (2012) Survivin expression induced by endothelin-1 promotes myofibroblast resistance to apoptosis. Interna-tional Journal of Biochemistry & Cell Biology, 44, 158-169. doi:10.1016/j.biocel.2011.10.011

[21]

Horowitz, J.C., et al. (2006) Constitutive activation of prosurvival signaling in alveolar mesenchymal cells isolated from patients with nonresolving acute respiratory distress syndrome. American Journal of Physiology— Lung Cellular and Molecular Physiology, 290, L415- L425. doi:10.1152/ajplung.00276.2005

[22]

Horowitz, J.C., et al. (2004) Activation of the pro-sur- vival phosphatidyli-nositol 3-kinase/AKT pathway by transforming growth factor-beta1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor. Journal of Biological Chemistry, 279, 1359-1367. doi:10.1074/jbc.M306248200

[23]

Horowitz, J.C., et al. (2007) Combinatorial activation of FAK and AKT by transforming growth factor-beta1 con- fers an anoi-kis-resistant phenotype to myofibroblasts. Cell Signal, 19, 761-771. doi:10.1016/j.cellsig.2006.10.001

[24]

Huang, S.K., et al. (2009) Prostaglandin E(2) induces fibroblast apoptosis by modulating multiple survival pathways. FASEB Journal, 23, 4317-4326. doi:10.1096/fj.08-128801

[25]

Xia, H., et al. (2004) Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibro- blast survival in response to contraction of type I collagen matrices via a beta 1 integrin viability signaling pathway. Journal of Biological Chemistry, 279, 33024-33034. doi:10.1074/jbc.M313265200

[26]

Rumble, J.M. and Duckett, C.S. (2008) Diverse functions within the IAP family. Journal of Cell Science, 121, 3505-3507. doi:10.1242/jcs.040303

[27]

Sah, N.K., et al. (2006) Structural, functional and therapeutic biology of survivin. Cancer Letters, 244, 164-171. doi:10.1016/j.canlet.2006.03.007

[28]

Altieri, D.C. (2010) Survivin and IAP proteins in cell- death mechanisms. Biochemical Journal, 430, 199-205. doi:10.1042/BJ20100814

[29]

Guha, M. and Altieri, D.C. (2009) Survivin as a global target of intrinsic tumor sup-pression networks. Cell Cycle, 8, 2708-2710. doi:10.4161/cc.8.17.9457

[30]

Altieri, D.C. (2008) New wirings in the survivin networks. Oncogene, 27, 6276-6284. doi:10.1038/onc.2008.303

[31]

White, E.S., et al. (2003) Integrin alpha4beta1 regulates migration across basement membranes by lung fibroblasts: a role for phosphatase and tensin homologue deleted on chro-mosome 10. American Journal of Respiratory and Critical Care Medicine, 168, 436-442. doi:10.1164/rccm.200301-041OC

[32]

Oikawa, T., et al. (2010) Identification of a small-mole- cule inhibitor of the interaction between Survivin and Smac/DIABLO. Biochemical and Biophysical Research Communications, 393, 253-258. doi:10.1016/j.bbrc.2010.01.113

[33]

Ryan, B.M., O’Donovan, N. and Duffy, M.J. (2009) Survivin: A new target for anti-cancer therapy. Cancer Treatment Reviews, 35, 553-562. doi:10.1016/j.ctrv.2009.05.003

[34]

Kulasekaran, P., et al. (2009) Endothelin-1 and trans- forming growth fac-tor-beta1 independently induce fibroblast resistance to apoptosis via AKT activation. American Journal of Res-piratory Cell and Molecular Biology, 41, 484-493. doi:10.1165/rcmb.2008-0447OC

[35]

Frankel, S.K., et al. (2006) TNF-alpha sensitizes normal and fibrotic human lung fibroblasts to Fas-induced apoptosis. American Journal of Respiratory Cell and Molecular Biology, 34, 293-304. doi:10.1165/rcmb.2005-0155OC

[36]

Huang, S.K., et al. (2008) Variable prostaglandin E2 resistance in fibroblasts from patients with usual interstitial pneumonia. American Journal of Respiratory and Critical Care Medicine, 177, 66-74. doi:10.1164/rccm.200706-963OC

[37]

Andersen, M.H., et al. (2007) The universal character of the tu-mor-associated antigen survivin. Clinical Cancer Research, 13, 5991-5994. doi:10.1158/1078-0432.CCR-07-0686

[38]

Kelly, R.J., et al. (2011) Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mo- lecular Cancer, 10, 35. doi:10.1186/1476-4598-10-35

[39]

Pavlyukov, M.S., et al. (2011) Survivin monomer plays an essential role in apoptosis regulation. Journal of Biological Chemistry, 286, 23296-23307. doi:10.1074/jbc.M111.237586

[40]

Nakahara, T., et al. (2011) YM155, a novel survivin sup- pressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anticancer Drugs, 22, 454-462. doi:10.1097/CAD.0b013e328344ac68

[41]

Anandharaj, A., Cinghu, S. and Park, W.Y. (2011) Ra- pamy-cin-mediated mTOR inhibition attenuates survivin and sensitizes glioblastoma cells to radiation therapy. Acta Biochim Biophys Sin (Shanghai) 43, 292-300 DOI: gmr012 [pii]10.1093/abbs/gmr012.

[42]

Hideshima, T., et al. (2007) Inhibition of Akt induces significant down-regulation of survivin and cytotoxicity in human multiple myeloma cells. British Journal of Haematology, 138, 783-791. doi:10.1111/j.1365-2141.2007.06714.x

[43]

Kang, H.R., et al. (2007) Semaphorin 7A plays a critical role in TGF-beta1-induced pulmonary fibrosis. Journal of Expe-rimental Medicine, 204, 1083-1093. doi:10.1084/jem.20061273

[44]

Le Cras, T.D., et al. (2010) Inhibition of PI3K by PX-866 prevents trans-forming growth factor-alpha-induced pul- monary fibrosis. American Journal of Pathology, 176, 679-686. doi:10.2353/ajpath.2010.090123

[45]

Marsillach, J., et al. (2008) Changes in the expression of genes related to apoptosis and fibrosis pathways in CCl4-treated rats. Molecular and Cellular Biochemistry, 308, 101-109. doi:10.1007/s11010-007-9617-0